紫杉醇联合卡铂化疗同步放疗治疗中晚期宫颈癌的近期疗效观察
Short term efficacy of paclitaxel combined with carboplatin in concurrent radiotherapy for advanced cervical cancer
闫莉 1张静 1杜文芳 1鲁耀华 1张习军 1程娟1
作者信息
- 1. 西安医学院附属宝鸡医院 妇产科,陕西 西安 721006
- 折叠
摘要
目的 分析紫杉醇联合卡铂化疗同步放疗治疗中晚期宫颈癌的近期疗效.方法 选取西安医学院附属宝鸡医院收治的60例晚期宫颈癌患者为研究对象,对照组进行单纯放疗,实验组患者给予紫杉醇联合卡铂化疗同步放疗治疗,紫杉醇135 mg/m2静脉滴注,静脉注射卡铂.比较分析实验组与对照组患者近期疗效、不良反应发生率等临床指标.结果 经过治疗后,实验组治疗有效率为80.0%,显著高于对照组有效率为50.0%,具有统计学意义(P<0.05).对照组不良反应发生率为53.3%显著高于实验组不良反应发生率为36.7%,具有统计学意义(P<0.05).结论 紫杉醇联合卡铂化疗同步放疗治疗中晚期宫颈癌近期疗效较为理想,安全性高,不良反应发生率低.
Abstract
Objective To study and analyze the short-term efficacy of paclitaxel combined with carboplatin chemotherapy in the treatment of advanced cervical cancer. Methods 60 cases of advanced cervical cancer patients in our hospital as the research object, the control group was treated by radiotherapy, patients in the experimental group were treated with paclitaxel and carboplatin chemotherapy combined radiotherapy treatment, paclitaxel 135 mg/m2 intravenous drip, intravenous injection of carboplatin. Comparative analysis of the experimental group and the control group of short-term efficacy, adverse reactions and other clinical indicators. Results The effective rate of the experimental group was 80.0%, which was significantly higher than that of the control group, and the effective rate was 50.0%, with statistical difference (P<0.05). The adverse reaction rate in the control group was 53.3%, which was significantly higher than that in the experimental group, and the adverse reaction rate was 36.7%, which was statistically significant (P<0.05). Conclusion Paclitaxel combined with carboplatin chemotherapy in the treatment of advanced cervical cancer with concurrent radiotherapy is effective, safe and low incidence of adverse reactions.
关键词
紫杉醇/卡铂/同步放疗/晚期宫颈癌/近期疗效Key words
paclitaxel/carboplatin/concurrent radiotherapy/advanced cervical cancer/short-term efficacy引用本文复制引用
出版年
2017
NETL
NSTL
万方数据